Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11312585 | 0.82 | SLC6A2 (0.33) | ALDH1A1SLC6A2HTR2AHTR2CSLC6A4 | |
| SCHEMBL13097294 | 0.78 | SLC6A2 (0.32) | ALDH1A1SLC6A2HTR2AHTR2CSLC6A4 | |
| SCHEMBL13349843 | 0.76 | SLC6A2 (0.30) | SLC6A2HTR2AHTR2CSLC6A4HTR7 | |
| SCHEMBL2384781 | 0.74 | SLC6A4 (0.36) | SLC6A2HTR2AHTR2CSLC6A4HTR7 | |
| SCHEMBL2149346 | 0.74 | SLC6A2 (0.36) | SLC6A2HTR2AHTR2CSLC6A4HTR7 | |
| SCHEMBL22006026 | 0.73 | SLC6A2 (0.31) | SLC6A2HTR2AHTR2CSLC6A4HTR7 | |
| SCHEMBL28124713 | 0.73 | PRKCA (0.33) | — | |
| Bromide SCHEMBL11401473 | 0.72 | SLC6A4 (0.35) | SLC6A2HTR2AHTR2CSLC6A4HTR7 | |
| Hydrochloric Acid SCHEMBL848632 | 0.72 | SLC6A4 (0.35) | SLC6A2HTR2AHTR2CSLC6A4HTR7 | |
| SCHEMBL19023307 | 0.72 | SLC6A2 (0.35) | SLC6A2HTR2AHTR2CSLC6A4HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | ALDH1A1 524/4885SLC6A2 1834/4885HTR2A 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.